Trials / Recruiting
RecruitingNCT06911203
A Study of BGM0504 in Participants With Obesity
A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGM0504 | Administered SC |
| DRUG | Tirzepatide | Administered SC |
Timeline
- Start date
- 2025-04-03
- Primary completion
- 2026-01-11
- Completion
- 2026-01-11
- First posted
- 2025-04-04
- Last updated
- 2025-10-28
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06911203. Inclusion in this directory is not an endorsement.